Tumor cell AMPK activation enhances NK cell anti-tumor immunity and synergizes with PD-L1 blockade therapy

Puntos clave

• NK cell anti-tumor immunity is significantly enhanced by tumor cell AMPK activation, which improves overall immune response.
• Enhanced cytokine production in NK cells correlates with PD-L1 blockade effectiveness, highlighting a promising therapeutic avenue.
• Approach involved in vitro and in vivo experiments to assess interactions between tumor cells and NK cells under AMPK modulation.
• Findings suggest a potential synergy between AMPK activation and PD-L1 blockade, calling for further investigation in clinical settings.